Simulations Plus (NASDAQ:SLP) Issues FY 2026 Earnings Guidance

Key Points

• Simulations Plus (NASDAQ:SLP) has updated its FY 2026 earnings guidance, projecting an EPS of 1.030-1.100 and revenue between $79.0 million-$82.0 million, surpassing consensus estimates.
• Brokerages have varied opinions on the stock, with four analysts rating it as Buy, five as Hold, and one as Sell, while the average price target is $24.40.
• The stock opened at $15.56 and has a market capitalization of $313.22 million, with institutional investors owning over 78% of the company's shares.

Simulations Plus (NASDAQ:SLP - Get Free Report) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 1.030-1.100 for the period, compared to the consensus EPS estimate of 0.870. The company issued revenue guidance of $79.0 million-$82.0 million, compared to the consensus revenue estimate of $80.0 million. Simulations Plus also updated its FY 2025 guidance to 1.030-1.030 EPS.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SLP. TD Cowen began coverage on Simulations Plus in a report on Tuesday, September 30th. They issued a "hold" rating and a $16.00 price target for the company. Cowen assumed coverage on Simulations Plus in a research report on Tuesday, September 30th. They set a "hold" rating for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Simulations Plus in a research report on Wednesday, October 8th. Stephens reduced their price objective on Simulations Plus from $28.00 to $20.00 and set an "overweight" rating for the company in a research report on Tuesday, July 15th. Finally, BTIG Research reduced their price objective on Simulations Plus from $41.00 to $25.00 and set a "buy" rating for the company in a research report on Monday, July 7th. Four analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $24.40.

Simulations Plus Stock Performance

Shares of SLP stock opened at $15.56 on Wednesday. Simulations Plus has a 1 year low of $12.39 and a 1 year high of $37.67. The stock has a fifty day moving average of $14.89 and a two-hundred day moving average of $20.65. The firm has a market capitalization of $313.22 million, a PE ratio of -4.94 and a beta of 0.99.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SLP. Raymond James Financial Inc. acquired a new position in Simulations Plus during the 2nd quarter worth $25,000. State of Tennessee Department of Treasury boosted its position in Simulations Plus by 182.9% during the 2nd quarter. State of Tennessee Department of Treasury now owns 11,191 shares of the technology company's stock worth $195,000 after acquiring an additional 7,235 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Simulations Plus by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company's stock worth $233,000 after acquiring an additional 390 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Simulations Plus in the first quarter valued at $255,000. Finally, Osaic Holdings Inc. lifted its holdings in shares of Simulations Plus by 11,780.3% in the second quarter. Osaic Holdings Inc. now owns 15,682 shares of the technology company's stock valued at $274,000 after buying an additional 15,550 shares during the period. Institutional investors and hedge funds own 78.08% of the company's stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.